Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

Podcasts
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Table of contents

November 2004 - Volume 63 - suppl 2

Advances in targeted therapies VI

Preface

Advances in targeted therapies VI (12 October, 2004)
F C Breedveld, J R Kalden, J S Smolen

Consensus statement

Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004 (12 October, 2004)
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J W J Bijlsma, M Dougados, P Emery, E C Keystone, L Klareskog, P J Mease

Warm-up

Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues (12 October, 2004)
F Wolfe, K Michaud, E M DeWitt
Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection (12 October, 2004)
L H Calabrese, N Zein, D Vassilopoulos

Genetics

Pharmacogenetics in the rheumatic diseases (12 October, 2004)
B N Cronstein
What precedes development of rheumatoid arthritis? (12 October, 2004)
L Klareskog, L Alfredsson, S Rantapää-Dahlqvist, E Berglin, P Stolt, L Padyukov

Clinical aspects

Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? (12 October, 2004)
T Pincus, T Sokka
The International Classification of Functioning, Disability and Health (ICF) Core Sets for rheumatoid arthritis: a way to specify functioning (12 October, 2004)
G Stucki, A Cieza
Should infection still be considered as the most likely triggering factor for rheumatoid arthritis? (12 October, 2004)
S M Carty, N Snowden, A J Silman
New issues in tuberculosis (12 October, 2004)
S H E Kaufmann

New targets I—signal transduction

Nuclear factor (NF)-κB proteins: therapeutic targets (12 October, 2004)
I M Verma
Mitogen activated protein kinases as targets for development of novel anti-inflammatory drugs (12 October, 2004)
M Karin
B cell signalling as therapeutic target (12 October, 2004)
R H Carter
Targeting the Jak/STAT pathway for immunosuppression (12 October, 2004)
J J O’Shea

New targets II

DREAMing about arthritic pain (12 October, 2004)
H-Y M Cheng, J M Penninger

New targets III—pathways

A toll for T cell costimulation (12 October, 2004)
F Y Liew, M Komai-Koma, D Xu

New target disease

The utility of tumour necrosis factor blockade in orphan diseases (12 October, 2004)
E C Keystone

New targets IV

Chemokines: role in inflammation and immune surveillance (12 October, 2004)
B Moser, K Willimann
Toll-like receptors in rheumatoid arthritis joint destruction mediated by two distinct pathways (12 October, 2004)
C Ospelt, D Kyburz, M Pierer, R Seibl, M Kurowska, O Distler, M Neidhart, U Muller-Ladner, T Pap, R E Gay, S Gay
Defining a role for fibroblasts in the persistence of chronic inflammatory joint disease (12 October, 2004)
C D Buckley, A Filer, O Haworth, G Parsonage, M Salmon
Cell therapy for autoimmune diseases: does it have a future? (12 October, 2004)
A Radbruch, A Thiel

Issue Information

Table of Contents (PDF)